Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

about

Population Pharmacodynamic Analysis of Uric Acid-Lowering Effects of Febuxostat Based on Electronic Medical Records in Two Hospitals.

P2860

Q47239976-1A870051-15AE-4AF9-AEAE-D763EECF7FD4

P2860

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

Item

http://www.wikidata.org/entity/Q39278948

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@nl

type

Item

label

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@nl

prefLabel

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@en

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@nl

P1476

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

@en

P2093

Bishoy Kamel

http://www.w3.org/2001/XMLSchema#string

Garry G Graham

http://www.w3.org/2001/XMLSchema#string

Kenneth M Williams

http://www.w3.org/2001/XMLSchema#string

Kevin D Pile

http://www.w3.org/2001/XMLSchema#string

Richard O Day

http://www.w3.org/2001/XMLSchema#string

P2860

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol

EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)

An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition

Mechanism of inhibition of xanthine oxidoreductase by allopurinol: crystal structure of reduced bovine milk xanthine oxidoreductase bound with oxipurinol

Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.

Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of febuxostat, a non-purine selective inhibitor of xanthine oxidase.

The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.

P2888

s40262-016-0466-4

P304

459-475

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40262-016-0466-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27753003

http://www.w3.org/2001/XMLSchema#string

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

about

P2860

P2860

Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698